Related Experiment Video
Updated: Aug 7, 2026
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
Vitamin E analogues as anticancer agents: lessons from studies with alpha-tocopheryl succinate
Xiu-Fang Wang1, Lanfeng Dong, Yan Zhao
1Apoptosis Research Group, School of Medical Science, Griffith University, Southport, Queensland, Australia.
Abstract:
The new millennium has witnessed considerable decrease in a number of previously fatal pathologies, largely due to the advancement in molecular medicine and modern approaches to treatment. In spite of this success, neoplastic disease remains a serious problem due to several reasons. These include an exceedingly high variability of cancer cells even within the same type of tumour. Cancer cells, albeit of clonal origin, mutate so that they escape established treatments, resulting in the fatal outcome of current therapies. Moreover, there are types of cancer, such as mesotheliomas, that cannot be treated at present. A novel group of clinically interesting anticancer drugs has been a recent focus in the literature that hold substantial promise as selective anticancer drugs. These compounds, epitomised by alpha-tocopheryl succinate, comprise redox-silent analogues of vitamin E that have been shown to suppress several types of cancer in animal models, including breast, colon and lung cancer as well as mesotheliomas and melanomas, while being nontoxic to normal cells and tissues. It is now proven that the strong anticancer effect of vitamin E analogues stems from their propensity to induce selective apoptosis in malignant cells. The results point to the novel group of vitamin E analogues as promising agents applicable to different types of tumours.
Insights
Novel vitamin E analogues, like alpha-tocopheryl succinate, show promise as selective anticancer drugs. These compounds induce apoptosis in cancer cells, offering a potential new treatment for various tumors, including difficult-to-treat types.
Area of Science:
- Oncology
- Molecular Medicine
- Pharmacology
Background:
- Neoplastic disease remains a significant health challenge due to tumor cell variability and treatment resistance.
- Existing therapies are often ineffective against certain cancers, such as mesotheliomas.
- There is a need for novel, selective anticancer agents.
Purpose of the Study:
- To investigate the potential of novel vitamin E analogues as selective anticancer drugs.
- To evaluate the efficacy of these compounds against various cancer types in preclinical models.
- To understand the mechanism of action of these promising agents.
Main Methods:
- Administration of redox-silent vitamin E analogues, exemplified by alpha-tocopheryl succinate, to animal models.
- Assessment of anticancer effects on different tumor types, including breast, colon, lung, mesothelioma, and melanoma.
- Evaluation of compound toxicity on normal cells and tissues.
Main Results:
- Vitamin E analogues demonstrated significant suppression of multiple cancer types in animal models.
- These compounds were found to be non-toxic to normal cells and tissues.
- The anticancer effect is attributed to the induction of selective apoptosis in malignant cells.
Conclusions:
- Redox-silent vitamin E analogues represent a promising new class of selective anticancer drugs.
- These agents show potential for treating a wide range of tumors, including those currently untreatable.
- Further research into vitamin E analogues could lead to novel therapeutic strategies for cancer.
Related Concept Videos
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...